PMID- 21712708
OWN - NLM
STAT- MEDLINE
DCOM- 20111213
LR  - 20211020
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Print)
IS  - 0955-8810 (Linking)
VI  - 22
IP  - 5-6
DP  - 2011 Sep
TI  - Opioid antinociception, tolerance and dependence: interactions with the 
      N-methyl-D-aspartate system in mice.
PG  - 540-7
LID - 10.1097/FBP.0b013e328348ed08 [doi]
AB  - This study explored the involvement of N-methyl-D-aspartate (NMDA) in the effects 
      of mu-opioid agonists. A hot-plate procedure was used to assess antinociception 
      and tolerance in mice in which the NR1 subunit of the NMDA receptor was reduced 
      [knockdown (KD)] to approximately 10%, and in mice treated with the NMDA 
      antagonist, (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid 
      (LY235959). The mu opioid agonists, morphine, l-methadone and fentanyl, were 
      approximately three-fold less potent in the NR1 KD mice than in wild-type (WT) 
      controls; however, the development of morphine tolerance and dependence did not 
      differ markedly in the NR1 KD and the WT mice. Acute administration of the NMDA 
      antagonist, LY235959, produced dose-dependent, leftward shifts in the morphine 
      dose-effect curve in the WT mice, but not in the NR1 KD mice. Chronic 
      administration of LY235959 during the morphine tolerance regimen did not 
      attenuate the development of tolerance in the NR1 KD or the WT mice. These 
      results indicate that the NR1 subunit of the NMDA receptor does not play a 
      prominent role in mu opioid tolerance.
FAU - Dykstra, Linda A
AU  - Dykstra LA
AD  - Behavioral Neuroscience Program, Department of Psychology, University of North 
      Carolina, Chapel Hill, North Carolina 27599-3270, USA. ldykstra@unc.edu
FAU - Fischer, Bradford D
AU  - Fischer BD
FAU - Balter, Rebecca E
AU  - Balter RE
FAU - Henry, Fredrick E
AU  - Henry FE
FAU - Schmidt, Karl T
AU  - Schmidt KT
FAU - Miller, Laurence L
AU  - Miller LL
LA  - eng
GR  - R01-DA002749/DA/NIDA NIH HHS/United States
GR  - T32 DA007244-19/DA/NIDA NIH HHS/United States
GR  - R01 DA002749-32/DA/NIDA NIH HHS/United States
GR  - T32 DA007244/DA/NIDA NIH HHS/United States
GR  - R01 DA002749/DA/NIDA NIH HHS/United States
GR  - F31 DA025446/DA/NIDA NIH HHS/United States
GR  - T32 DA007244-18/DA/NIDA NIH HHS/United States
GR  - T32-DA007244/DA/NIDA NIH HHS/United States
GR  - R01 DA002749-31/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Isoquinolines)
RN  - 0 (NR1 NMDA receptor)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 0 (Receptors, Opioid, mu)
RN  - 76I7G6D29C (Morphine)
RN  - AR2BHC0C6P (LY 235959)
SB  - IM
MH  - Analgesics, Opioid/administration & dosage/*pharmacology
MH  - Animals
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Tolerance
MH  - Excitatory Amino Acid Antagonists/administration & dosage/pharmacology
MH  - Gene Knockdown Techniques
MH  - Isoquinolines/administration & dosage/pharmacology
MH  - Male
MH  - Mice
MH  - Morphine/administration & dosage/*pharmacology
MH  - Morphine Dependence/metabolism
MH  - Pain/*drug therapy
MH  - Receptors, N-Methyl-D-Aspartate/drug effects/genetics/*metabolism
MH  - Receptors, Opioid, mu/agonists
PMC - PMC3155647
MID - NIHMS305204
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2011/06/30 06:00
MHDA- 2011/12/14 06:00
PMCR- 2012/09/01
CRDT- 2011/06/30 06:00
PHST- 2011/06/30 06:00 [entrez]
PHST- 2011/06/30 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - 10.1097/FBP.0b013e328348ed08 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2011 Sep;22(5-6):540-7. doi: 10.1097/FBP.0b013e328348ed08.